1.
Trends Parasitol
; 37(1): 8-11, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33153922
RESUMO
Artemisinin-based combination therapies (ACTs) have demonstrated in vitro inhibition of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Artemisinins have also shown anti-inflammatory effects, including inhibition of interleukin-6 (IL-6) that plays a key role in the development of severe coronavirus disease 2019 (COVID-19). There is now sufficient evidence for the effectiveness of ACTs, and in particular artesunate/pyronaridine, to support clinical studies for COVID-19 infections.
Assuntos
Antimaláricos/uso terapêutico , Tratamento Farmacológico da COVID-19 , Reposicionamento de Medicamentos , Antivirais/uso terapêutico , Artemisininas/farmacologia , Artesunato/uso terapêutico , Síndrome da Liberação de Citocina/tratamento farmacológico , Combinação de Medicamentos , Humanos , Naftiridinas/uso terapêutico , SARS-CoV-2/efeitos dos fármacos
2.